Ventilator-Associated Pneumonia and Other Complications

Ventilator-associated pneumonia occurs in patients who have been intubated for two to three days with significant exposure to hospital-acquired organisms. Treatment should be initiated rapidly and cover P. aeruginosa, Escheriochia coli, Klebsiella pneumonia, and Acinetobacter species as well as meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Jennifer P., Howell, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120823/
http://dx.doi.org/10.1007/978-3-319-43341-7_29
_version_ 1783515061317271552
author Stevens, Jennifer P.
Howell, Michael D.
author_facet Stevens, Jennifer P.
Howell, Michael D.
author_sort Stevens, Jennifer P.
collection PubMed
description Ventilator-associated pneumonia occurs in patients who have been intubated for two to three days with significant exposure to hospital-acquired organisms. Treatment should be initiated rapidly and cover P. aeruginosa, Escheriochia coli, Klebsiella pneumonia, and Acinetobacter species as well as methicillin-resistant S. aureus. Within 72 h or with the availability of culture results, antibiotics should be narrowed. Active research is on-going to identify patients at risk for ventilator-associated complications and to minimize the likelihood of infection in these patients.
format Online
Article
Text
id pubmed-7120823
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-71208232020-04-06 Ventilator-Associated Pneumonia and Other Complications Stevens, Jennifer P. Howell, Michael D. Evidence-Based Critical Care Article Ventilator-associated pneumonia occurs in patients who have been intubated for two to three days with significant exposure to hospital-acquired organisms. Treatment should be initiated rapidly and cover P. aeruginosa, Escheriochia coli, Klebsiella pneumonia, and Acinetobacter species as well as methicillin-resistant S. aureus. Within 72 h or with the availability of culture results, antibiotics should be narrowed. Active research is on-going to identify patients at risk for ventilator-associated complications and to minimize the likelihood of infection in these patients. 2016-07-21 /pmc/articles/PMC7120823/ http://dx.doi.org/10.1007/978-3-319-43341-7_29 Text en © Springer International Publishing Switzerland 2017 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Stevens, Jennifer P.
Howell, Michael D.
Ventilator-Associated Pneumonia and Other Complications
title Ventilator-Associated Pneumonia and Other Complications
title_full Ventilator-Associated Pneumonia and Other Complications
title_fullStr Ventilator-Associated Pneumonia and Other Complications
title_full_unstemmed Ventilator-Associated Pneumonia and Other Complications
title_short Ventilator-Associated Pneumonia and Other Complications
title_sort ventilator-associated pneumonia and other complications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120823/
http://dx.doi.org/10.1007/978-3-319-43341-7_29
work_keys_str_mv AT stevensjenniferp ventilatorassociatedpneumoniaandothercomplications
AT howellmichaeld ventilatorassociatedpneumoniaandothercomplications

Ejemplares similares